DE3675748D1 - System zur gesteuerten freisetzung von wirksubstanzen. - Google Patents

System zur gesteuerten freisetzung von wirksubstanzen.

Info

Publication number
DE3675748D1
DE3675748D1 DE8686116649T DE3675748T DE3675748D1 DE 3675748 D1 DE3675748 D1 DE 3675748D1 DE 8686116649 T DE8686116649 T DE 8686116649T DE 3675748 T DE3675748 T DE 3675748T DE 3675748 D1 DE3675748 D1 DE 3675748D1
Authority
DE
Germany
Prior art keywords
polymeric material
deposit
swelling
core
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686116649T
Other languages
English (en)
Inventor
Paolo Colombo
Manna Aldo La
Ubaldo Conte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Jagotec AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11206044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3675748(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jagotec AG filed Critical Jagotec AG
Application granted granted Critical
Publication of DE3675748D1 publication Critical patent/DE3675748D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE8686116649T 1985-12-20 1986-12-01 System zur gesteuerten freisetzung von wirksubstanzen. Expired - Lifetime DE3675748D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT23321/85A IT1188212B (it) 1985-12-20 1985-12-20 Sistema per il rilascio a velocita' controllata di sostanze attive

Publications (1)

Publication Number Publication Date
DE3675748D1 true DE3675748D1 (de) 1991-01-03

Family

ID=11206044

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686116649T Expired - Lifetime DE3675748D1 (de) 1985-12-20 1986-12-01 System zur gesteuerten freisetzung von wirksubstanzen.

Country Status (11)

Country Link
US (1) US4839177A (de)
EP (1) EP0226884B1 (de)
JP (1) JP2535339B2 (de)
AT (1) ATE58472T1 (de)
AU (1) AU594992B2 (de)
CA (1) CA1298479C (de)
DE (1) DE3675748D1 (de)
ES (1) ES2018468B3 (de)
GR (1) GR3001141T3 (de)
IT (1) IT1188212B (de)
NZ (1) NZ218596A (de)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US6005094A (en) * 1986-10-28 1999-12-21 Genta Incorporated Oligonucleotide analogues having improved stability at acid pH
IT1201136B (it) * 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
GB8707416D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US4892778A (en) * 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4814181A (en) * 1987-09-03 1989-03-21 Alza Corporation Dosage form comprising fast agent delivery followed by slow agent delivery
DE3737741A1 (de) * 1987-11-06 1989-05-18 Goedecke Ag Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid
IT1223150B (it) * 1987-11-18 1990-09-12 Ubaldo Conte Compressa per uso oftalmico e rilascio controllato della sostanza attiva
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
US5045082A (en) * 1990-01-10 1991-09-03 Alza Corporation Long-term delivery device including loading dose
DE4021678C2 (de) * 1990-07-07 1994-07-07 Merz & Co Gmbh & Co Verfahren zur Herstellung klein dimensionierter Formkörper mit hohem Etofibrat-Gehalt und kontrollierter Wirkstoff-Freisetzung, deren Verwendung und daraus bestehende oral verabreichbare Applikationsformen
US5342628A (en) * 1990-10-11 1994-08-30 Applied Medical Research, Inc. Drug diffusion polymer system and method
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IL108206A0 (en) * 1993-01-06 1994-04-12 Univ Johns Hopkins Oligomers having improved stability at acid ph
IL109460A (en) 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6183778B1 (en) 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
IT1265240B1 (it) * 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
JP3720386B2 (ja) * 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
CA2123332C (en) * 1994-05-11 1997-02-04 Bernard Charles Sherman Controlled release formulation of diltiazem hydrochloride
US5453924A (en) * 1994-05-16 1995-09-26 Ag-Chem Equipment Company, Inc. Mobile control system responsive to land area maps
NZ270078A (en) * 1994-12-06 1998-05-27 Bernard Charles Sherman Diltiazem hydrochloride formulation comprising beads with immediate, intermediate, and delayed release dissolution profiles
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US5830503A (en) * 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
HU228007B1 (en) * 1996-08-29 2012-08-28 Jagotec Ag Tablet with controlled release of alfuzosine chlorydrate
US6074669A (en) * 1997-01-20 2000-06-13 Ranbaxy Laboratories Limited Controlled drug delivery system for diltiazem
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
EP1003476B1 (de) * 1997-08-11 2004-12-22 ALZA Corporation Gastrische zurückhalteform zur verlängerten freisetzung eines wirkstoffs
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
IT1294760B1 (it) 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6365183B1 (en) * 1998-05-07 2002-04-02 Alza Corporation Method of fabricating a banded prolonged release active agent dosage form
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
WO2000038650A1 (en) * 1998-12-23 2000-07-06 Alza Corporation Gastric retention dosage form having multiple layers
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
WO2001047498A2 (en) 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
AU767812B2 (en) 2000-02-04 2003-11-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
US6607694B1 (en) * 2000-03-31 2003-08-19 Dober Chemical Corp. Controlled release coolant additive composition
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
PT1276470E (pt) 2000-04-20 2007-08-13 Novartis Ag Composição de revestimento para dissimular o sabor
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US6720005B1 (en) 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
WO2002072033A2 (en) 2001-03-13 2002-09-19 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms containing glucocorticosteroid
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6960357B2 (en) * 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
HUP0401079A3 (en) * 2001-07-10 2008-04-28 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
ITMI20012481A1 (it) * 2001-11-23 2003-05-23 Univ Parma Sistemi modulari per il rilascio controllato di sostanza a controllo spaziale e temporale
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
EP1465606A4 (de) * 2001-12-24 2009-04-22 Teva Pharma Dosierungsform mit einem von einem verpressten ringförmigen körper aus pulver- oder granulatmaterial umhüllten tablettenkern aus aktivem bestandteil sowie verfahren und gerät zur herstellung davon
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
JP3811127B2 (ja) * 2003-01-30 2006-08-16 株式会社東芝 情報記録装置及び情報記録方法
US20040213850A1 (en) * 2003-04-25 2004-10-28 Eleni Dokou Sustained release delivery of a thrombin inhibitor
GB0319874D0 (en) * 2003-08-22 2003-09-24 Glaxo Group Ltd Novel formulation
US10226428B2 (en) 2003-09-19 2019-03-12 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
AP2006003602A0 (en) * 2003-09-19 2006-04-30 Sun Pharmaceutical Ind Ltd Oral drug delivery system
US10213387B2 (en) 2003-09-19 2019-02-26 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
JP2008508227A (ja) * 2004-07-29 2008-03-21 サノフイ−アベンテイス 高ｐｈ依存性溶解度を有する有効成分の放出制御のための医薬品多層錠剤
US20060024368A1 (en) * 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8389578B2 (en) 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
KR101406456B1 (ko) * 2005-04-06 2014-06-20 아다마스 파마슈티칼스, 인코포레이티드 Ｃｎｓ 장애의 치료를 위한 방법 및 조성물
RU2008104638A (ru) * 2005-07-07 2009-08-20 Фарнэм Компаниз, Инк. (Us) Фармацевтические композиции хорошо растворимых в воде лекарственных средств, обеспечивающих их замедленное высвобождение
US8778395B2 (en) 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
WO2007035816A2 (en) * 2005-09-20 2007-03-29 Dr. Reddy's Laboratories Ltd. Paroxetine compositions
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
BRPI0620863A8 (pt) 2005-12-29 2018-01-16 Osmotica Kereskedelmi Es Szolgaltato Kft comprimido em camadas com combinação de liberação tripla
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
US9011930B2 (en) * 2006-05-01 2015-04-21 Zycal Bioceuticals Healthcare Company, Inc. Nutritional supplement and use thereof
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
CA2664641A1 (en) 2006-09-26 2008-04-10 Astellas Pharma, Inc. Controlled release dosage form of tacrolimus
EP2101713A1 (de) * 2006-12-05 2009-09-23 Universita' Degli Studi Di Parma Neue module, neue anordnungssets und neue anordnungen für die kontrollierte freisetzung von substanzen
CA2674039A1 (en) * 2006-12-28 2008-07-17 Astellas Pharma Inc. Sustained release formulation for tacrolimus
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
KR20100136967A (ko) * 2008-02-15 2010-12-29 썬 파마 어드밴스트 리서치 컴패니 리미티드 파열 효과가 감소된 방출 제어 경구 정제
JP2009281159A (ja) 2008-05-19 2009-12-03 Honda Motor Co Ltd 内燃機関の排気浄化装置
US20100291238A1 (en) * 2008-07-21 2010-11-18 Michael Cherkassky Appetite suppressant product and method
WO2010015029A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
NZ592765A (en) * 2008-08-14 2013-06-28 Bioneer As Tablets with a coating which impedes the release of an active ingredient
GB0817120D0 (en) * 2008-09-19 2008-10-29 Diurnal Ltd Treatment of adrenal insufficiency
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
WO2010077925A2 (en) 2008-12-16 2010-07-08 Teva Pharmaceutical Industries Ltd. Drug delivery system for zero order, zero order biphasic, ascending or descending drug delivery of methylphenidate
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US9259394B2 (en) * 2009-12-07 2016-02-16 Johnson & Johnson Consumer Inc. Partial dip coating of dosage forms for modified release
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10485770B2 (en) 2009-12-21 2019-11-26 Aptapharma, Inc. Functionally-coated multilayer tablets
CN102740830A (zh) * 2009-12-23 2012-10-17 普西维达公司 缓释递送装置
EP2521537A2 (de) 2010-01-04 2012-11-14 Wockhardt Limited Pharmazeutische zusammensetzung zur modifizierten freisetzung von wirkstoffen
TR201802207T4 (tr) 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.
US20130230586A1 (en) 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
EP2651399A2 (de) 2010-12-13 2013-10-23 Purdue Pharma LP Retard-darreichungsformen
RU2013135224A (ru) 2011-01-20 2015-03-10 Бионевиа Фармасьютикалс Инк. Композиции с модифицированным высвобождением эпалрестата или его производных и способы их использования
JP2014508187A (ja) 2011-03-17 2014-04-03 ルピン・リミテッド 選択的セロトニン再取り込み阻害薬の放出制御医薬組成物
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
AU2013213317B2 (en) 2012-01-23 2016-06-30 Sun Pharmaceutical Industries Limited In-situ multilayered tablet technology
CN103371982A (zh) * 2012-04-20 2013-10-30 王进京 盐酸帕罗西汀肠溶控释片新型处方组成及制备方法
ITMI20121263A1 (it) 2012-07-19 2014-01-20 Recordati Ind Chimica E Farma Ceutica S P A Forma farmaceutica multistrato
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
USD741471S1 (en) * 2013-10-01 2015-10-20 John F. LaGratta Cylindrical tablet having separable mating components
KR102266091B1 (ko) 2013-10-07 2021-06-17 임팩스 라보라토리즈, 인코포레이티드 레보도파 및/또는 레보도파의 에스테르의 점막-점착성, 제어 방출형 제제 그리고 이의 용도
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US20150133516A1 (en) 2013-11-13 2015-05-14 Brian K. Adams Methods and Compositions for Treating ADHD
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US20180362974A1 (en) 2015-07-02 2018-12-20 University Of Louisville Research Foundation, Inc. EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1022171A (en) * 1961-06-15 1966-03-09 Wellcome Found Prolonged release oral pharmaceutical tablets and their manufacture
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
FR2100858B1 (de) * 1970-07-03 1975-06-06 Daiichi Seiyaku Co
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
JPS58134019A (ja) * 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
IT8523321A0 (it) 1985-12-20
EP0226884B1 (de) 1990-11-22
JPS62155211A (ja) 1987-07-10
JP2535339B2 (ja) 1996-09-18
ATE58472T1 (de) 1990-12-15
AU6672586A (en) 1987-06-25
NZ218596A (en) 1989-08-29
GR3001141T3 (en) 1992-06-25
CA1298479C (en) 1992-04-07
EP0226884A3 (en) 1988-06-01
AU594992B2 (en) 1990-03-22
EP0226884A2 (de) 1987-07-01
US4839177A (en) 1989-06-13
IT1188212B (it) 1988-01-07
ES2018468B3 (es) 1991-04-16

Similar Documents

Publication Publication Date Title
ATE58472T1 (de) System zur gesteuerten freisetzung von wirksubstanzen.
KR850007559A (ko) 조절 펩타이드의 삽입식 제형
ES516375A0 (es) Procedimiento para la obtencion de una composicion a base de estireno para revestir alimentos y medicamentos.
NO740153L (no) Anvendelse av tørre partikler av en i vann uoppløselig men til gel begrenset svellbar hydrofil polymer som væskeabsorberende material i hjelpemidler for rengjøring av væskende hud-, sår- eller slimhinneoverflater.
BR9604455A (pt) Utilizaçao de um sistema polimérico utilizaç o de um sistema polimerico ou composiçao composiçao capaz de ser aplicada á pele ás semimucosas e as mucosas e composiçao de batom para os lábios sem transferéncia
ATE135906T1 (de) Tabletten mit gesteuerter wirkstoffabgabe
ATE47312T1 (de) Zusammensetzung in form einer emulsion mit einem gehalt von polyenantibiotikum.
ATE180409T1 (de) Kollagenzubereitung zur gesteuerten abgabe von wirkstoffen
ES2019658B3 (es) Procedimiento de bombeo para la mezcla artificial de dos liquidos en cantidades iguales y dispositivo de bombeo para efectuar este procedimiento.
AU587753B2 (en) Dry material which can be hydrated into an aqueous gel, containing dispersed polymer particles, process for the preparation thereof and use thereof in biological applications
BR9508440A (pt) Gel capaz de ser disperso em água sistema de conteinerização compreendendo o mesmo e processo para preparar o gel
ES2064673T3 (es) Procedimiento de tratamiento biologico de una superficie artificial.
ATE268172T1 (de) Verfahren zur herstellung von fenofibrat- präparaten
ES2061475T3 (es) Masa polimerica basica, adhesiva, permeable al principio activo, procedimiento para su obtencion y uso.
DE3678643D1 (de) Partikel mit konstanter wirkstofffreisetzung.
DE58903858D1 (de) Polymerisierbare aryldiazosulfonate und polymere enthaltend wiederkehrende einheiten mit aryldiazosulfonatgruppen.
DE3678641D1 (de) Partikel mit konstanter wirkstofffreisetzung.
FI98271B (fi) Paisuneita makromolekyylejä sisältävän vesiseosjärjestelmän käyttö sammutusvetenä
ES8601756A1 (es) Metodo de fabricar una estructura compuesta coherente.
EP0308947A3 (de) Verfahren zur Vermischung von lebenden Zellen oder Mikro-organismen mit einer viskosen Flüssigkeit und Mischungen, die nach diesem Verfahren hergestellt wurden
DE220965T1 (de) Polymere zusammensetzung zur geregelten freisetzung von wirkstoffen.
DE69016344D1 (de) Verwendung von wasserlöslichen ionenen Polymeren zur Verhütung von Bakterienansätzen und zum Reduzieren von biologischer Verschmutzung in wässerigen Systemen.
ES2033927T3 (es) Utilizacion de la forma farmaceutica de "gel" conteniendo acido n-(2,6-cicloro-m-tolil)-antranilico (acido meclofenamico) utilizable en terapia de uso topico.
JPS6434492A (en) Biomembrane carrier for water treatment
ES2085892T3 (es) Composicion suavizante de tejidos.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition